Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests
April 28, 2017 10:40 AM EDT
Jefferies raised its price target on Exact Sciences (NASDAQ: EXAS) to $35.00 (from $25.00) while maintaining a Buy rating. Test volumes surged to ~100K units compared to Jefferies' ~88K expectations, reflecting a sharp acceleration from its run-rate over the past year.
EXAS raised its 2017... More
April 27, 2017 3:35 PM EDT
Cowen raised its price target on Exact Sciences (NASDAQ: EXAS) to $40.00 (from $30.00) while maintaining a Outperform rating following a solid start to the year.
Analyst Doug Schenkel noted revenue, new practice additions, and total orders were well ahead of expectations. In... More
April 27, 2017 6:23 AM EDT
Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.32), $0.09 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $48.4 million versus the consensus estimate of $37.29 million.
GUIDANCE:
Exact Sciences sees FY2017 revenue of $195-205 million, versus the consensus... More
